NCT05199519

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

A Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 in Patients With CLDN18.2-positive Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors

Conditions

• CLDN18.2 Positive Solid Tumors

Interventions

Type	Name	Description
DRUG	IBI345	IBI345 CAR-T cell injection by intravenous infusion

Timeline

• Start date: 2021-12-13
• Primary completion: 2022-10-29
• Completion: 2023-01-19
• First posted: 2022-01-20
• Last updated: 2023-05-24

Locations

1 site across 1 country: China